3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Sarcoma
1
Gastrointestinal
1
Conditions
Sarcoma
4
Ovarian Neoplasms
3
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinosarcoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Teratoma, Testicular
1
Teratoma, Ovarian
1
Teratoma
1
Stomach Neoplasms
1
Stage IA Uterine Sarcoma
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Recurrence
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
39
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
30
Busulfan
26
Filgrastim
24
Cyclosporine
24
Mycophenolic Acid
22
Antilymphocyte Serum
22
Radiotherapy
20
Melphalan
16
Whole-Body Irradiation
15
Tacrolimus
14
Methylprednisolone
14
Methotrexate
13
Cord Blood Stem Cell Transplantation
12
Etoposide
10
sargramostim
5
Thiotepa
5
Temozolomide
5
Sirolimus
5
Rituximab
5
Bevacizumab
5
aldesleukin
4
Therapeutics
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
Carmustine
4
pembrolizumab
3
Vincristine
3
Topotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Taxes
×
Sarcoma
×
Clear all
NCT03275818
2022-06-07
ABRADES
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Completed
69 enrolled